CA2222101A1 - 2-((1h)-4(5)-imidazoyl)cyclopropyl derivatives - Google Patents

2-((1h)-4(5)-imidazoyl)cyclopropyl derivatives Download PDF

Info

Publication number
CA2222101A1
CA2222101A1 CA002222101A CA2222101A CA2222101A1 CA 2222101 A1 CA2222101 A1 CA 2222101A1 CA 002222101 A CA002222101 A CA 002222101A CA 2222101 A CA2222101 A CA 2222101A CA 2222101 A1 CA2222101 A1 CA 2222101A1
Authority
CA
Canada
Prior art keywords
imidazoyl
compound
pharmaceutically acceptable
cyclopropyl
cyclopropanamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002222101A
Other languages
English (en)
French (fr)
Inventor
James G. Phillips
Clark E. Tedford
Amin Mohammed Khan
Stephen L. Yates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gliatech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2222101A1 publication Critical patent/CA2222101A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Paints Or Removers (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002222101A 1995-05-30 1996-05-29 2-((1h)-4(5)-imidazoyl)cyclopropyl derivatives Abandoned CA2222101A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/453,359 1995-05-30
US08/453,359 US5652258A (en) 1995-05-30 1995-05-30 2-(4-imidazoyl) cyclopropyl derivatives

Publications (1)

Publication Number Publication Date
CA2222101A1 true CA2222101A1 (en) 1996-12-05

Family

ID=23800267

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002222101A Abandoned CA2222101A1 (en) 1995-05-30 1996-05-29 2-((1h)-4(5)-imidazoyl)cyclopropyl derivatives

Country Status (17)

Country Link
US (2) US5652258A (https=)
EP (1) EP0837679B1 (https=)
JP (1) JP2001503013A (https=)
KR (1) KR19990022137A (https=)
CN (1) CN1100534C (https=)
AT (1) ATE207354T1 (https=)
AU (1) AU713767B2 (https=)
CA (1) CA2222101A1 (https=)
DE (1) DE69616328T2 (https=)
DK (1) DK0837679T3 (https=)
ES (1) ES2163019T3 (https=)
FI (1) FI974363L (https=)
MX (1) MX9709211A (https=)
NO (1) NO975484D0 (https=)
NZ (1) NZ308410A (https=)
PT (1) PT837679E (https=)
WO (1) WO1996038141A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652258A (en) * 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives
US6008240A (en) * 1997-12-15 1999-12-28 Gliatech, Inc. 2-(1H-4(5)-imidazoyl) cyclopropyl derivatives
JP2002534511A (ja) 1999-01-18 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 置換型イミダゾール、それらの調製及び使用
US7265115B2 (en) 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6114350A (en) * 1999-04-19 2000-09-05 Nen Life Science Products, Inc. Cyanine dyes and synthesis methods thereof
US6437147B1 (en) 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
US6610721B2 (en) 2000-03-17 2003-08-26 Novo Nordisk A/S Imidazo heterocyclic compounds
WO2002013821A1 (en) 2000-08-17 2002-02-21 Gliatech, Inc. Novel alicyclic imidazoles as h3 agents
AU2001283573A1 (en) * 2000-08-21 2002-03-04 Gliatech, Inc. The use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity
AU2002256967A1 (en) * 2000-10-30 2002-09-12 Schering Corporation Treating or reducing the risk of cardiovascular disease
CA2477391A1 (en) * 2002-03-01 2003-09-12 Denis Schrier Method of treating osteoarthritis
EP1720847A1 (en) * 2004-02-02 2006-11-15 Pfizer Products Incorporated Histamine-3 receptor modulators
US7902191B2 (en) 2004-02-25 2011-03-08 Eli Lilly And Company Histamine H3 receptor antagonists, preparation and therapeutic uses
SI1735278T1 (sl) 2004-04-01 2010-05-31 Lilly Co Eli Agenti histamin h receptorja priprava in terapevtska uporaba
AU2005252178B2 (en) * 2004-06-02 2011-04-21 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
ES2534605T3 (es) 2004-08-23 2015-04-24 Eli Lilly And Company Agentes receptores de la histamina H3, preparación y usos terapéuticos
US7846950B2 (en) 2004-10-18 2010-12-07 Eli Lilly And Company Histamine H3 receptor inhibitors, preparation and therapeutic uses
AU2006227815B2 (en) 2005-03-17 2011-09-22 Eli Lilly And Company Pyrrolidine derivatives as histamine H3 receptor antagonists
AU2006232871B9 (en) 2005-04-01 2011-11-24 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
EP1707203A1 (en) 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
EP1717233A1 (en) * 2005-04-29 2006-11-02 Bioprojet Histamine H3-receptor ligands and their therapeutic application
EP1717235A3 (en) 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
CA2622597A1 (en) * 2005-09-15 2007-03-22 Banyu Pharmaceutical Co., Ltd. Histamine h3 agonist for use as therapeutic agent for lipid/glucose metabolic disorder
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
RU2602814C2 (ru) 2009-09-25 2016-11-20 Оризон Дженомикс С.А. Лизинспецифические ингибиторы деметилазы-1 и их применение
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
RS55348B1 (sr) 2010-04-19 2017-03-31 Oryzon Gnomics S A Inhibitori lizin specifične demetilaze-1 i njihova upotreba
WO2012013728A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
WO2012107498A1 (en) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative disorders
MX356344B (es) 2011-10-20 2018-05-23 Oryzon Genomics Sa Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1.
RU2668952C2 (ru) 2011-10-20 2018-10-05 Оризон Дженомикс, С.А. (гетеро)арилциклопропиламины в качестве ингибиторов lsd1
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2671083B1 (fr) * 1990-12-31 1994-12-23 Inst Nat Sante Rech Med Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
JPH06505265A (ja) * 1991-02-27 1994-06-16 シード・キャピタル・インベストメント・（エス・シー・アイ）・ベスローテン・フェンノートシャップ ヒスタミンｈ↓３受容体に対する作動的または拮抗的活性を有するイミダゾール誘導体
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5217986A (en) * 1992-03-26 1993-06-08 Harbor Branch Oceanographic Institution, Inc. Anti-allergy agent
US5652258A (en) * 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives

Also Published As

Publication number Publication date
ES2163019T3 (es) 2002-01-16
WO1996038141A1 (en) 1996-12-05
EP0837679A1 (en) 1998-04-29
FI974363A7 (fi) 1997-11-28
EP0837679B1 (en) 2001-10-24
PT837679E (pt) 2002-03-28
AU713767B2 (en) 1999-12-09
MX9709211A (es) 1998-07-31
US5990317A (en) 1999-11-23
DE69616328T2 (de) 2002-07-04
JP2001503013A (ja) 2001-03-06
CN1100534C (zh) 2003-02-05
AU5804796A (en) 1996-12-18
DE69616328D1 (de) 2001-11-29
US5652258A (en) 1997-07-29
KR19990022137A (ko) 1999-03-25
CN1192143A (zh) 1998-09-02
FI974363A0 (fi) 1997-11-28
NO975484D0 (no) 1997-11-28
EP0837679A4 (en) 1999-03-03
FI974363L (fi) 1997-11-28
ATE207354T1 (de) 2001-11-15
DK0837679T3 (da) 2002-02-11
NZ308410A (en) 2001-06-29

Similar Documents

Publication Publication Date Title
CA2222101A1 (en) 2-((1h)-4(5)-imidazoyl)cyclopropyl derivatives
AU721325B2 (en) 1H-4(5)-substituted imidazole derivatives
JP3560986B2 (ja) ５―ｈｔ２ｃ受容体作用薬及びアミノアルキルインダゾール誘導体
US6794405B2 (en) Alicyclic imidazoles as H3 agents
US6710064B2 (en) Hydantoin compounds useful as anti-inflammatory agents
US6448282B1 (en) 1H-4(5)-substituted imidazole derivatives
WO2005118573A1 (en) Novel diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors
JP6317345B2 (ja) ウレア化合物および酵素阻害剤としてのそれらの使用
AU713166B2 (en) 1H-4(5)-substituted imidazole derivatives
US6008240A (en) 2-(1H-4(5)-imidazoyl) cyclopropyl derivatives
EP0279937B1 (en) 2-aminoacetamide derivatives
CA2309609A1 (en) Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
JP3850920B2 (ja) アズレン誘導体およびその製造方法ならびにタキキニン受容体拮抗剤
US6072057A (en) 1H-4(5)-cyclo-substituted imidazole derivatives as histamine H3 receptor agents
MXPA97009210A (en) Derivatives of imidazol ih-4 (5) -substitui
RU2114828C1 (ru) Энантиомеры ароматических азотсодержащих производных и их соли с неорганическими или органическими кислотами и способ их получения
AU9725598A (en) Non-peptide tachykinin receptor antagonists

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued